Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Graillon

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Discover Oncology|May 5, 2026
Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature reviewAdèle Meola, Romain Appay, Benoit Testud, et al.
Neuro-Oncology Advances|July 10, 2020
Brief CommunicationCirculating tumor DNA is present in the most aggressive meningiomasThomas Graillon, Catherine Roche, Noémie Basset, et al.
Neuro-Oncology Practice|November 27, 2023
Radio-chemotherapy feasibility for biopsy-only unresectable <i>IDH</i> wild-type glioblastomas (BO-GBM)Vincent Harlay, Romain Appay, Céline Bequet, et al.
Journal of Neuro-Oncology|October 16, 2025
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomasVincent Harlay, Céline Bequet, Romain Appay, et al.
International Journal of Molecular Sciences|July 24, 2021
Somatotroph Tumors and the Epigenetic Status of the <i>GNAS</i> LocusPauline Romanet, Justine Galluso, Peter Kamenicky, et al.
Journal of the Neurological Sciences|March 8, 2022
Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapyBrice Chanez, Romain Appay, Arnaud Guille, et al.
Neuro-Oncology|March 7, 2024
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomasEmeline Tabouret, Julia Furtner, Thomas Graillon, et al.
Acta Neuropathologica Communications|January 4, 2022
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary studyCarine Jiguet-Jiglaire, Sebastien Boissonneau, Emilie Denicolai, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysisChristian Mirian, Anne Katrine Duun-Henriksen, Andrea Maier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM TrialThomas Graillon, Marc Sanson, Chantal Campello, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Discover Oncology|May 5, 2026
Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature reviewAdèle Meola, Romain Appay, Benoit Testud, et al.
Neuro-Oncology Advances|July 10, 2020
Brief CommunicationCirculating tumor DNA is present in the most aggressive meningiomasThomas Graillon, Catherine Roche, Noémie Basset, et al.
Neuro-Oncology Practice|November 27, 2023
Radio-chemotherapy feasibility for biopsy-only unresectable <i>IDH</i> wild-type glioblastomas (BO-GBM)Vincent Harlay, Romain Appay, Céline Bequet, et al.
Journal of Neuro-Oncology|October 16, 2025
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomasVincent Harlay, Céline Bequet, Romain Appay, et al.
International Journal of Molecular Sciences|July 24, 2021
Somatotroph Tumors and the Epigenetic Status of the <i>GNAS</i> LocusPauline Romanet, Justine Galluso, Peter Kamenicky, et al.
Journal of the Neurological Sciences|March 8, 2022
Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapyBrice Chanez, Romain Appay, Arnaud Guille, et al.
Neuro-Oncology|March 7, 2024
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomasEmeline Tabouret, Julia Furtner, Thomas Graillon, et al.
Acta Neuropathologica Communications|January 4, 2022
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary studyCarine Jiguet-Jiglaire, Sebastien Boissonneau, Emilie Denicolai, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysisChristian Mirian, Anne Katrine Duun-Henriksen, Andrea Maier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM TrialThomas Graillon, Marc Sanson, Chantal Campello, et al.
Pageof 11